ストックスクリーナーアプリを入手
18.00
1.75%
-0.32
プレマーケット:
18.08
0.08
+0.44%
前日終値:
$18.32
開ける：
$17.625
24時間の取引高:
1.72M
Relative Volume:
1.31
時価総額：
$1.49B
収益：
$46.02M
当期純損益:
$-70.80M
株価収益率:
-9.8901
EPS:
-1.82
ネットキャッシュフロー:
$-1.61M
1週間 パフォーマンス:
+1.35%
1か月 パフォーマンス:
+45.99%
6か月 パフォーマンス:
+51.52%
1年 パフォーマンス:
+196.05%
1日の値動き範囲:
$17.14
$18.45
1週間の範囲:
$16.92
$18.87
52週間の値動き範囲:
$3.91
$19.11
Eyepoint Inc Stock (EYPT) Company Profile
Compare EYPT vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
EYPT
Eyepoint Inc
|
18.00 | 1.52B | 46.02M | -70.80M | -1.61M | -1.82 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.89 | 120.48B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.50 | 81.05B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
749.56 | 46.33B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.30 | 42.26B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
299.02 | 32.87B | 5.36B | 287.73M | 924.18M | 2.5229 |
Eyepoint Inc Stock (EYPT) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-06-17 | 開始されました | RBC Capital Mkts | Outperform |
| 2025-01-07 | 開始されました | Citigroup | Buy |
| 2024-10-16 | 開始されました | Scotiabank | Sector Outperform |
| 2024-08-28 | 開始されました | Jefferies | Buy |
| 2024-01-22 | 開始されました | JP Morgan | Overweight |
| 2023-11-02 | 開始されました | Mizuho | Buy |
| 2023-04-21 | 開始されました | Robert W. Baird | Outperform |
| 2022-07-07 | 開始されました | Chardan Capital Markets | Buy |
| 2021-03-01 | 開始されました | Cowen | Outperform |
| 2021-01-28 | 開始されました | Cantor Fitzgerald | Overweight |
| 2020-04-06 | ダウングレード | B. Riley FBR | Buy → Neutral |
| 2019-11-04 | 再開されました | Laidlaw | Buy |
| 2019-09-12 | 開始されました | Guggenheim | Buy |
すべてを表示
Eyepoint Inc (EYPT) 最新ニュース
EyePoint (EYPT) Analyst Rating Update: Price Target Increased to $30 | EYPT Stock News - GuruFocus
EyePoint: The 'Pre-Readout' Surge Is Hiding A Commercial Reality Check (NASDAQ:EYPT) - Seeking Alpha
EyePoint (EYPT) Q4 2025 Earnings Call Transcript - The Globe and Mail
Is It Too Late To Consider EyePoint (EYPT) After A 1‑Year Surge And DCF Upside? - simplywall.st
EyePoint: Fourth Quarter Financial Results Overview - Bitget
EyePoint Inc (EYPT) Q4 2025 Earnings Call Highlights: Navigating Revenue Decline Amid Promising Clinical Advances - GuruFocus
Chardan raises EyePoint stock price target to $29 on cash position - Investing.com UK
EYPT (EyePoint) Equity-to-Asset : 0.80 (As of Sep. 2025) - GuruFocus
EYPT (EyePoint) ROE % : -107.10% (As of Sep. 2025) - GuruFocus
Chardan Capital Issues Positive Forecast for Eyepoint Pharmaceuticals (NASDAQ:EYPT) Stock Price - MarketBeat
Chardan Capital Raises Price Target for EYPT to $29.00, Maintains Buy Rating | EYPT Stock News - GuruFocus
Eyepoint Pharmaceuticals (NASDAQ:EYPT) Stock Price Down 4.7%Should You Sell? - MarketBeat
Earnings call transcript: Eyepoint Pharmaceuticals Q4 2025 reveals revenue drop - Investing.com South Africa
EyePoint Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Eyepoint Pharmaceuticals Q4 Earnings Call Highlights - MarketBeat
EYPT: DURAVYU's pivotal Phase III trials progress with strong safety, efficacy, and funding into 2027 - TradingView
EYPT: DURAVYU advanced in pivotal trials with strong cash reserves and key data readouts ahead - TradingView
EyePoint Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Eyepoint Pharma earnings missed by $0.06, revenue fell short of estimates - Investing.com Canada
EyePoint, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2025 - marketscreener.com
EyePoint Inc (NASDAQ:EYPT) Stock Falls on Q4 Earnings and Revenue Miss - ChartMill
EyePoint (EYPT) Reports Q4 Loss, Tops Revenue Estimates - Nasdaq
EyePoint Pharmaceuticals' Q4 Net Loss Widens, Revenue Drops - marketscreener.com
Earnings Flash (EYPT) EyePoint Posts Q4 Net Loss $0.81 a Share, vs. FactSet Est of $0.77 Loss - marketscreener.com
Earnings Flash (EYPT) EyePoint, Inc. Reports Q4 Revenue $620,000, vs. FactSet Est of $990,000 - marketscreener.com
EYPT Forecasts Financial Stability Through Key Program Milestones - GuruFocus
EYEPOINT PHARMACEUTICALS ($EYPT) Releases Q4 2025 Earnings - Quiver Quantitative
EyePoint: Q4 Earnings Snapshot - marketscreener.com
EyePoint Reports Fourth Quarter and Full-Year 2025 Financial Results and Highlights Recent Corporate Developments - TradingView
EYPT: DURAVYU Phase 3 trials progress, with strong cash reserves funding operations into Q4 2027 - TradingView
EyePoint (Nasdaq: EYPT) deepens 2025 loss while pushing DURAVYU into Phase 3 - Stock Titan
Earnings Summary: EyePoint Q4 - Benzinga
EyePoint at TD Cowen Conference: DURAVYU’s Market Potential By Investing.com - Investing.com Canada
EYPT: Phase 3 trials advance with unique IL-6 mechanism, targeting a $15B global retina market - TradingView
A Preview Of EyePoint Pharmaceuticals's Earnings - Benzinga
EyePoint Pharmaceuticals to Announce Q4 Earnings on March 4 - Intellectia AI
Eyepoint Pharma earnings up next as pivotal trial data looms By Investing.com - Investing.com Canada
Eyepoint Pharma earnings up next as pivotal trial data looms - Investing.com Nigeria
EyePoint Pharmaceuticals Experiences Revision in Stock Evaluation Amid Strong Performance Metrics - Markets Mojo
EyePoint begins dosing in phase 3 DME trials for DURAVYU - Eyes On Eyecare
EYPT Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
EyePoint doses first patients in phase 3 DME trials for DURAVYU - Investing.com Australia
Eyepoint Inc topline data for Duravyu in dme anticipated in 2h 2027 - marketscreener.com
Eyepoint Inc Topline Data For Duravyu In Dme Anticipated In 2H 2027 - TradingView
EyePoint Doses First Patients in Phase 3 Trials of Duravyu in Diabetic Macular Edema - marketscreener.com
EyePoint Starts Global Phase 3 Trials for DURAVYU - TipRanks
EyePoint doses first patients in Phase 3 COMO and CAPRI trials for DURAVYU in DME - TradingView
EyePoint (EYPT) doses first patients in DURAVYU Phase 3 DME trials - Stock Titan
Six-month EyePoint eye implant in late-stage tests for diabetic vision loss - Stock Titan
Is EyePoint (EYPT) Recasting Its Ophthalmology Playbook With a Veteran Launch Executive at DURAVYU? - simplywall.st
EyePoint, Inc. (EYPT) Stock Analysis: Unpacking The 103% Potential Upside - DirectorsTalk Interviews
Eyepoint Inc (EYPT) 財務データ
収益
当期純利益
現金流量
EPS
0.11%
6.00%
大文字化:
|
ボリューム (24 時間):